Biodesy Closes on $15M Series A Round, Appoints Greg Yap as CEO | GenomeWeb

NEW YORK (GenomeWeb News) – Biotech firm Biodesy said today that it has closed a $15 million Series A financing round with investments from 5AM Ventures, Pfizer Venture Investments, and Roche Venture Fund.

Additionally, the company announced that it has named Greg Yap as CEO and a director. Biodesy founder Joshua Salafsky has been appointed as chief science officer and a director.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.